Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)
Status:
Unknown status
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The trial is a random, open, control and monocentric trial. Mainly to assess the urine
protein remission rate of tacrolimus (TAC) monotherapy for idiopathic membranous nephropathy
(IMN). Assuming that the urine protein remission rate of 48-week TAC for monotherapy of IMN
is not lower than that in treatment group of TAC combined with glucocorticoid, attempt on
de-hormonal therapy in the future IMN therapy can be attempted on the basis of the trial
results.
Phase:
N/A
Details
Lead Sponsor:
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine